NL-OMON47985RecruitingNot Applicable
Adalimumab dose optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trail - ADDORA
Jan van Breemen Instituut0 sites267 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 267
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Rheumatoid arthritis patient, according to ACR 1987 /2010 criteria;
- •Starting adalimumab as the first biological therapy
- •Written informed consent
- •Age 18 years or older.
Exclusion Criteria
- •Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;
- •Life expectancy shorter than follow-up period of the study;
- •Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trailRheumatoid arthritisEUCTR2019-001554-25-NLReade267
Recruiting
Not Applicable
Adalimumab drug optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trailRheumatoid arthritisNL-OMON26185Reade Rheumatology Research Institute267
Active, not recruiting
Phase 1
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers.Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)Reumatoid artritisMedDRA version: 12.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidEUCTR2009-014394-41-DKHvidovre Hospital
Recruiting
Phase 4
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringRheumatoid ArthritisNCT04194827Reade Rheumatology Research Institute267
Completed
Phase 4
Efficacy of HUMIRA in Subjects With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00234897Abbott1,938